SearchDictionaryMobileLogin

Christie M Ballantyne Selected Research

Atherosclerosis (Atheroma)

06/2008Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.
05/2008Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden.
02/2008Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study.
11/2007Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study.
07/2007Interaction effects of high-density lipoprotein metabolism gene variation and alcohol consumption on coronary heart disease risk: the atherosclerosis risk in communities study.
05/2007A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) Study.
02/2007Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study.
07/2006An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study.
05/2006P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities Study.
11/2005Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
11/2005Apolipoprotein E genotype and incident ischemic stroke: the Atherosclerosis Risk in Communities Study.
09/2004Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study.
03/2004Relationship between low-density lipoprotein subclasses and asymptomatic atherosclerosis in subjects from the Atherosclerosis Risk in Communities (ARIC) Study.
02/2004Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
01/2004Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study.
12/2003Glutathione-S-transferase genotypes, smoking, and their association with markers of inflammation, hemostasis, and endothelial function: the atherosclerosis risk in communities (ARIC) study.
08/2002Soluble adhesion molecules and the search for biomarkers for atherosclerosis.

Articles by Research Topic

Disease

17Atherosclerosis (Atheroma)
06/2008 - 08/2002
11Coronary Disease (Coronary Heart Disease)
04/2008 - 04/2003
8Hypercholesterolemia
11/2007 - 01/2003
7Syndrome
01/2006 - 03/2003
5Stroke (Strokes)
02/2008 - 11/2005
4Dyslipidemias (Dyslipidemia)
04/2008 - 01/2004
4Inflammation
06/2004 - 01/2002
3Cardiovascular Diseases (Cardiovascular Disease)
05/2008 - 11/2003
3Tissue Adhesions
05/2007 - 08/2002
3Coronary Artery Disease (Coronary Atherosclerosis)
05/2005 - 11/2002
1Coronary Stenosis (Coronary Artery Stenosis)
05/2008
1Hypertension (High Blood Pressure)
05/2008
1Flushing
03/2008
1Vascular Diseases (Vascular Disease)
04/2007
1Lipodystrophy
12/2006
1Infection
04/2006
1Hyperlipidemias (Hyperlipidemia)
03/2006
1Obesity
07/2005
1Arthritis (Polyarthritis)
03/2005
1Brain Injuries (Brain Injury)
12/2004
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
12/2004
1Autoimmune Diseases (Autoimmune Disease)
08/2004
1Weight Loss (Weight Reduction)
06/2004
1Bacteremia
04/2003

Drug/Important Bio-Agent (IBA)

7rosuvastatin (Crestor)FDA Link
05/2008 - 01/2003
6ezetimibe (Zetia)FDA Link
03/2007 - 05/2003
6Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA
04/2006 - 01/2002
6atorvastatin (Lipitor)FDA Link
03/2005 - 01/2003
5Simvastatin (Zocor)FDA LinkGeneric
03/2005 - 06/2003
4LDL CholesterolIBA
06/2008 - 05/2003
4Biological Markers (Surrogate Marker)IBA
04/2008 - 08/2002
4Niacin (Nicotinic Acid)FDA LinkGeneric
04/2008 - 03/2006
4C-Reactive ProteinIBA
07/2006 - 02/2004
3CholesterolIBA
06/2008 - 01/2004
31-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA
04/2008 - 02/2004
3HDL CholesterolIBA
04/2008 - 11/2003
3Lipoproteins (Lipoprotein)IBA
07/2007 - 01/2004
2PPAR alphaIBA
06/2008 - 01/2004
2P-SelectinIBA
11/2007 - 05/2006
2ApolipoproteinsIBA
08/2006 - 11/2005
2AdiponectinIBA
09/2004 - 06/2004
2LipidsIBA
01/2004 - 11/2002
2fluvastatinFDA Link
01/2004 - 11/2002
2Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
12/2003 - 04/2003
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2003 - 01/2002
1Complement Factor H (Factor H)IBA
05/2008
1MK-0524IBA
03/2008
1Cyclooxygenase 2 (Cyclooxygenase-2)IBA
02/2008
1P-selectin ligand proteinIBA
11/2007
1CXC ChemokinesIBA
05/2007
1Ferritins (Ferritin)IBA
05/2007
1Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA
05/2007
1Glucose (Dextrose)FDA LinkGeneric
02/2007
1Procetofen (CiL)FDA LinkGeneric
12/2006
1Genetic Markers (Genetic Marker)IBA
05/2005
1ezetimibe-simvastatin combination (Vytorin)FDA Link
03/2005
15'-palmitoyl cytarabine (PLAC)IBA
01/2005
1Cholestyramine (Questran)FDA LinkGeneric
11/2004
1Carbon MonoxideIBA
06/2004
1Nonesterified Fatty Acids (NEFA)IBA
01/2004
1Glutathione Transferase (Glutathione S-Transferase)IBA
12/2003
1IntegrinsIBA
04/2003
1ThrombomodulinIBA
04/2003

Therapy/Procedure

1Caloric Restriction
06/2004